Purpose of Technology: Sofosbuvir-velpatasvir (Epclusa) is a “next-generation” once-daily direct-acting antiretroviral (DAA) combination oral regimen for the treatment of all 6 major hepatitis C virus (HCV) genotypes. The fixed-dose combination pill contains 400 mg of sofosbuvir and 100 mg of velpatasvir.
Rationale: Sofosbuvir-velpatasvir is intended to treat any genotype and subtype of HCV using an existing drug with accepted efficacy, plus a new drug that is intended to improve efficacy by targeting HCV in a different way.
Does sofosbuvir-velpatasvir result in high rates of sustained virologic response (SVR) and low rates of treatment failure (i.e., virologic relapse)?
How does sofosbuvir-velpatasvir compare with other treatments for HCV for increasing SVR rates, reducing treatment failure (i.e., virologic relapse) rates, or improving patient-oriented outcomes (e.g., quality of life)?
What harms and complications are associated with sofosbuvir-velpatasvir?
Have definitive patient selection criteria been established for sofosbuvir-velpatasvir for treatment of chronic HCV infection?
If you have a Hayes login, click here to view the full report on the Knowledge Center.